RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
Anthera receives orphan drug status for the prevention of acute chest syndrome in patients with sickle cell disease
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted A-001 orphan drug status for the prevention of acute chest syndrome in patients with sickle cell disease.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.